How Gilgamesh Landed a $1.2B AbbVie Deal in Psychedelics
Unable to add items
Add to basket failed.
Add to wishlist failed.
Failed to remove from Wish List.
Adding to library failed
Unable to follow podcast
Unable to unfollow podcast
How Gilgamesh Landed a $1.2B AbbVie Deal in Psychedelics
-
Narrated by:
-
By:
Jonathan Sporn (CEO + Founder of Gilgamesh Pharma) joins for a deep dive into next-gen psychedelic medicines, why duration matters for real-world clinical use, and what it takes to build these therapies the way large pharma would—culminating in a partnership with AbbVie worth up to $1.2B.
In this episode, we discuss:
• Why Gilgamesh is building psychedelic medicines the way large pharma would
• The thesis behind short-acting psychedelics and why long-duration trips are impractical for real-world psychiatry
• How Gilgamesh designs molecules backwards from clinical needs
• Effective approaches to the challenges of trial designs for psychedelics
• What AbbVie’s deal and Spravato’s trajectory mean for psychedelics
• How psychedelic medicines could reshape mental health
Credits:
Created by Greg Kubin and Matias Serebrinsky
Host: Matias and Greg
Produced by Nico V. Rey
Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank